OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model - Anses - Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail Access content directly
Journal Articles Frontiers in Immunology Year : 2023

OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model

Abstract

Spike-based COVID-19 vaccines induce potent neutralizing antibodies but their efficacy against SARS-CoV-2 variants decreases. OVX033 is a recombinant protein composed of the full-length nucleocapsid (N) protein of SARS-CoV-2 genetically fused to oligoDOM ® , a self-assembling domain which improves antigen immunogenicity. OVX033 including N as an antigenic target is proposed as new vaccine candidate providing broad-spectrum protection against sarbecoviruses. OVX033 demonstrated its ability to trigger cross-reactive T cell responses and cross-protection against three variants of SARS-CoV-2 (B.1 Europe, Delta B.1.617.2, and Omicron B.1.1.529) in a hamster challenge model, as evidenced by lower weight loss, lower lung viral loads, and reduced lung histopathological lesions.
Fichier principal
Vignette du fichier
fimmu-14-1188605.pdf (2.64 Mo) Télécharger le fichier
Origin Publisher files allowed on an open archive
Licence

Dates and versions

anses-04145238 , version 1 (29-06-2023)

Licence

Identifiers

Cite

Charlotte Primard, Elodie Monchâtre-Leroy, Judith del Campo, Séverine Valsesia, Elsa Nikly, et al.. OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model. Frontiers in Immunology, 2023, 14, pp.1188605. ⟨10.3389/fimmu.2023.1188605⟩. ⟨anses-04145238⟩

Collections

ANSES EMERGIN
443 View
60 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More